Hydrodynamic, mass transfer, and dissolution effects induced by tablet location during dissolution testing

Journal of Pharmaceutical Sciences

Volumn 98, Issue 4, 2009, Pages 1511-1531

  Bai, G E ^a   Armenante, Piero M ^a  

^a NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CFD; Computational fluid dynamics; Dissolution testing; Mass transfer coefficient; Modeling; USB dissolution testing apparatus ii

Indexed keywords

PREDNISONE; SALICYLIC ACID;

ARTICLE; CORRELATION ANALYSIS; DISSOLUTION; DRUG ABSORPTION; DRUG SOLUBILITY; EXPERIMENTATION; HYDRODYNAMICS; PREDICTION; TABLET FORMULATION; VELOCITY;

EID: 67349144268     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21512     Document Type: Article

References (32)

1. Pharmacopoeial Convention Inc. 2005. The United States Pharmacopeia &The National Formulary. The Official Compendia of Standards, USP 29-NF24 2005. Pharmacopoeial Convention Inc., November 2005.
2. Cohen JL, Hubert BB, Leeson LJ, Rhodes CT, Robinson JR, Roseman TJ, Shefter E. 1990. The development of USP dissolution and drug release standards. Pharm Res 7:983-987.
3. Mauger J, Ballard J, Brockson R, De S, Gray V, Robinson D. 2003. Intrinsic dissolution performance of the USP dissolution apparatus 2 (rotating paddle) using modified salicylic acid calibration tablets: Proof of principle. Dissol Technol 10:6-15.
4. Moore TW, Hamilton JF, Kerner CM. 1995. Dissolution testing: Limitation of USP Prednisone and salicylic acid calibrator tablets. Pharmacopeial Forum 21:1387-1396.
5. Qureshi SA, McGilveray IJ. 1999. Typical variability in drug dissolution testing: Study with USP and FDA calibrator tablets and a marketed drug Glibenclamide product. Eur J Pharm Sci 7:249-258.
6. Qureshi SA, Shabnam J. 2001. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Eur J Pharm Sci 12:271-276.
7. Costa P, Lobo JMS. 2001. Influence of dissolution medium agitation on release profiles of sustained- release tablets. Drug Dev Ind Pharm 27:811-817.
8. Bocanegra LM, Morris GJ, Jurewicz JT, Mauger JW. 1990. Fluid and particle laser Doppler velocity measurements and mass transfer predictions for USP paddle method dissolution apparatus. Drug Dev Ind Pharm 16:1441-1464.
9. Cox DC, Furman WB. 1982. Systematic error associated with Apparatus 2 of the USP dissolution test I: Effects of physical alignment of the dissolution apparatus. J Pharm Sci 71:451-452.
10. Cox DC, Furman WB, Thornton LK. 1983. Systematic error associated with apparatus 2 of the USP dissolution test III: Limitation of calibrators and the USP suitability test. J Pharm Sci 72:910-913.
11. Kukura J, Arratia PC, Szalai ES, Muzzio FJ. 2003. Engineering tools for understanding hydrodynamics of dissolution tests. Drug Dev Ind Pharm 29:231-239.
12. Baxter JL, Kukura J, Muzzio FJ. 2005. Hydrodynamics-induced variability in the USP apparatus II dissolution Test. Int J Pharm 292:17-28.
13. FDC Reports. 2001. Recalls Prompted By FDA on the Increase. The Gold Sheet 35 (1).
14. FDC Reports. 2002. Counterfeits Pose Special Recall Challenge. The Gold Sheet 36 (1).
15. FDC Reports. 2003. Spike in Potency-Related Problems Contributes to Overall Rise in 2002 Recalls. The Gold Sheet 37 (1).
16. McCarthy L, Bradley G, Sexton G, Corrigan O, Healy AM. 2004. Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate mixing patterns and fluid velocities. AAPS Pharm Sci Tech 5:Article 31.
17. McCarthy L, Kosiol C, Healy AM, Bradley G, Sexton J, Corrigan 0. 2003. Simulating the hydro- dynamic conditions in the United States Pharmacopeias paddle dissolution apparatus. AAPS Pharm Sci Tech 4:Article 22.
18. Kukura J, Baxter JL, Muzzio FJ. 2004. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions. Int J Pharm 279: 9-17.
19. Bai G, Armenante PM, Plank RV, Gentzler M, Ford K, Harmon P. 2007. Hydrodynamic investigation of USP dissolution test apparatus II. J Pharm Sci 96:2327-2349.
20. Bai G, Armenante PM, Plank RV. 2007. Experimental and computational determination of blend time in USP dissolution testing apparatus II. J Pharm. Sci 96:3072-3086.
21. Bai G, Armenante PM. 2008. Velocity distribution and shear rate variability resulting from changes in the impeller location in the USP Dissolution Testing Apparatus II. Pharm Res 25:320-336.
22. Division of Drug Analysis. 1995. Food and Drug Administration. Dissolution Test Performance Standard #2.
23. United States Pharmacopeia. 2006. USP Certificate, USP Salicylic Acid Tablets RS, Lot Q0D200.
24. Moore JW, Flanner HH. 1996. Mathematical comparison of dissolution profiles. Pharm Technol 20:64-74.
25. Costa P, Lobo JMS. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123-133.
26. Food and Drug Administration. 1997. Guidance for Industry-Dissolution Testing of Immediate Release Solid Oral Dosage Forms.
27. Abdoun HM, Hanna S, Muhammad N. 2000. Chapter 35, Dissolution. In: Gennaro AR, editor. Remington: The science and practice of pharmacy. 20th edition. Philadelphia, PA: Lippincott, Williams and Wilkins.
28. Armenante PM, Kirwan DJ. 1989. Mass transfer to microparticles in agitated systems. Chem Eng Sci 44:2781-2796.
29. Middleman S. 1998. An introduction to mass and heat transfer. New York: John Wiley &Sons, Inc.
30. Bird RB, Stewart EW, Lightfoot NE. 2002.Transport phenomena. New York: John Wiley &Sons, Inc.
31. Geankoplis JC. 2003. Transport processes and separation process principles. Upper Saddle River, New Jersey: Prentice Hall.
32. Labraga L, Berkah T. 2004. Mass transfer from a rotating cylinder with and without crossflow. Int J Heat Mass Transf 47:2493-2499.